

Raquel Sanchez-Valle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1317273/publications.pdf>

Version: 2024-02-01

277
papers

12,461
citations

31976

53
h-index

37204

96
g-index

313
all docs

313
docs citations

313
times ranked

13279
citing authors

#	ARTICLE	IF	CITATIONS
1	Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. <i>Brain</i> , 2023, 146, 321-336.	7.6	30
2	Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2023, 273, 243-252.	3.2	8
3	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Applied Neuropsychology Adult</i> , 2022, 29, 112-119.	1.2	18
4	Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases. <i>Brain</i> , 2022, 145, 700-712.	7.6	16
5	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 158-168.	1.9	7
6	Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 336-339.	1.9	1
7	Baseline MRI atrophy predicts 2-year cognitive outcomes in early-onset Alzheimer's disease. <i>Journal of Neurology</i> , 2022, 269, 2573-2583.	3.6	6
8	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1805-1817.	7.6	27
9	Prion diseases. <i>European Neuropsychopharmacology</i> , 2022, 55, 1-3.	0.7	0
10	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum τ and pNfH : A Longitudinal Multicentre Study. <i>Annals of Neurology</i> , 2022, 91, 33-47.	5.3	21
11	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 10.	6.2	4
12	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-14.	2.6	3
13	Assessment of Cognitive Symptoms in Brain Bank-Registered Control Subjects: Feasibility and Utility of a Telephone-Based Screening. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1107-1113.	2.6	0
14	Cortical microstructure in primary progressive aphasia: a multicenter study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 27.	6.2	10
15	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2022, 150, 12-28.	2.4	2
16	Data-driven staging of genetic frontotemporal dementia using multi-modal τ MRI. <i>Human Brain Mapping</i> , 2022, 43, 1821-1835.	3.6	7
17	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 1408-1423.	0.8	24
18	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2022, , .	3.1	1

#	ARTICLE	IF	CITATIONS
19	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. <i>Journal of Neurology</i> , 2022, 269, 4322-4332.	3.6	1
20	The CBI&R detects early behavioural impairment in genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 644-658.	3.7	1
21	A neurodegenerative disease landscape of rare mutations in Colombia due to founder effects. <i>Genome Medicine</i> , 2022, 14, 27.	8.2	16
22	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 761-771.	1.9	12
23	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
24	CSF Biomarkers in COVID-19 Associated Encephalopathy and Encephalitis Predict Long-Term Outcome. <i>Frontiers in Immunology</i> , 2022, 13, 866153.	4.8	57
25	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. <i>Neurology</i> , 2022, 99, .	1.1	5
26	Evolution of Clinical-Pathological Correlations in Early-Onset Alzheimer's Disease Over a 25-Year Period in an Academic Brain Bank. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1659-1669.	2.6	5
27	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	9.0	31
28	Bioenergetic and Autophagic Characterization of Skin Fibroblasts from C9orf72 Patients. <i>Antioxidants</i> , 2022, 11, 1129.	5.1	2
29	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. <i>Neurobiology of Aging</i> , 2021, 99, 99.e15-99.e22.	3.1	8
30	Biphasic cortical macro&and microstructural changes in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 618-628.	0.8	27
31	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 500-514.	0.8	36
32	Presentations and mechanisms of CNS disorders related to COVID-19. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	52
33	Errorless Learning Therapy in Semantic Variant of Primary Progressive Aphasia. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 415-422.	2.6	6
34	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. <i>Alzheimer's and Dementia</i> , 2021, 17, 969-983.	0.8	31
35	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. <i>JAMA Network Open</i> , 2021, 4, e2030194.	5.9	42
36	Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 494-501.	1.9	27

#	ARTICLE	IF	CITATIONS
37	Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants. <i>Brain Pathology</i> , 2021, 31, e12942.	4.1	9
38	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021, 17, 1329-1341.	0.8	34
39	Detection of α -synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. <i>Lancet Neurology</i> , The, 2021, 20, 203-212.	10.2	174
40	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 608-616.	1.9	10
41	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. <i>JAMA Network Open</i> , 2021, 4, e211290.	5.9	12
42	CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2021, 103, 158.e1-158.e5.	3.1	8
43	TREM2 expression in the brain and biological fluids in prion diseases. <i>Acta Neuropathologica</i> , 2021, 141, 841-859.	7.7	18
44	Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid β positivity. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1037-1049.	2.7	6
45	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2021, 96, e2296-e2312.	1.1	52
46	Characterizing the Clinical Features and Atrophy Patterns of <i>MAPT</i> -Related Frontotemporal Dementia With Disease Progression Modeling. <i>Neurology</i> , 2021, 97, e941-e952.	1.1	29
47	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
48	Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1456-1470.	3.7	19
49	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	30.7	182
50	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 127.	6.2	12
51	Pioglitazone for prevention of cognitive impairment: results and lessons. <i>Lancet Neurology</i> , The, 2021, 20, 500-502.	10.2	1
52	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. <i>Neurobiology of Aging</i> , 2021, 108, 155-167.	3.1	3
53	Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson's disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 367-382.	6.1	21
54	Differential early subcortical involvement in genetic FTD within the GENFI cohort. <i>NeuroImage: Clinical</i> , 2021, 30, 102646.	2.7	28

#	ARTICLE	IF	CITATIONS
55	Disease-related cortical thinning in presymptomatic granulin mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 29, 102540.	2.7	8
56	Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2021, 32, 102804.	2.7	28
57	<i>SLITRK2</i> , an X-linked modifier of the age at onset in <i>C9orf72</i> frontotemporal lobar degeneration. <i>Brain</i> , 2021, 144, 2798-2811.	7.6	7
58	Accelerated long-term forgetting over three months in asymptomatic APOE ε4 carriers. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 477-484.	3.7	7
59	Homozygous R136S mutation in PRNP gene causes inherited early onset prion disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 176.	6.2	1
60	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. <i>Molecular Neurodegeneration</i> , 2021, 16, 79.	10.8	9
61	Homozygous R136S mutation in PRNP gene causes inherited early onset prion disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 176.	6.2	8
62	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	4
63	Detecting clinical progression from abnormal regional brain volumes at baseline in genetic frontotemporal dementia: A GENFI study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
64	Agreement of amyloid PET and CSF biomarkers in a clinical cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
65	ALTOIDA-ADL for the diagnosis of Mild Cognitive Impairment and early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, e057982.	0.8	1
66	A data-driven disease progression model of fluid biomarkers in genetic FTD. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
67	Impact of COVID-19 pandemic in an early-onset dementia clinic in Barcelona. <i>Alzheimer's and Dementia</i> , 2021, 17, e052114.	0.8	0
68	Atrophy patterns in sporadic and genetic behavioral variant frontotemporal dementia reflect brain network architecture. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
69	The location of <i>PSEN1</i> pathogenic variants in transmembrane vs. cytoplasmic domains may alter neurodegenerative and cognitive trajectories: Findings from the DIAN study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
70	Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. <i>Alzheimer's and Dementia</i> , 2020, 16, 262-272.	0.8	47
71	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 87, 139.e1-139.e7.	3.1	35
72	Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study. <i>Alzheimer's and Dementia</i> , 2020, 16, 292-304.	0.8	29

#	ARTICLE	IF	CITATIONS
73	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	10.2	175
74	Sex Differences of Longitudinal Brain Changes in Cognitively Unimpaired Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1413-1422.	2.6	4
75	Use of Antipsychotics in Patients with Behavioral and Psychological Symptoms of Dementia: Results of a Spanish Delphi Consensus. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 573-582.	1.5	5
76	LifeTime and improving European healthcare through cell-based interceptive medicine. <i>Nature</i> , 2020, 587, 377-386.	27.8	108
77	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 975-984.	1.9	25
78	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in <i>C9orf72</i> expansion carriers in the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1325-1328.	1.9	12
79	Effects of <i>IgLN5</i> Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration. <i>Annals of Neurology</i> , 2020, 88, 1023-1027.	5.3	61
80	<i>C9orf72</i> , age at onset, and ancestry help discriminate behavioral from language variants in FTL cohorts. <i>Neurology</i> , 2020, 95, e3288-e3302.	1.1	7
81	Digital biomarker-based individualized prognosis for people at risk of dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12073.	2.4	28
82	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. <i>Brain Communications</i> , 2020, 2, .	3.3	20
83	Functional network alterations in early-onset Alzheimer's disease studied with resting-state fMRI. <i>Alzheimer's and Dementia</i> , 2020, 16, e043307.	0.8	0
84	Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	29
85	Autoantibodies against the prion protein in individuals with <i>PRNP</i> mutations. <i>Neurology</i> , 2020, 95, e2028-e2037.	1.1	7
86	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 263-270.	1.9	106
87	Diagnostic Accuracy of MRI Visual Rating Scales in the Diagnosis of Early Onset Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1575-1583.	2.6	12
88	Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures. <i>Human Brain Mapping</i> , 2020, 41, 2004-2013.	3.6	22
89	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 612-621.	1.9	55
90	Screening of dementia genes by whole-exome sequencing in Spanish patients with early-onset dementia: likely pathogenic, uncertain significance and risk variants. <i>Neurobiology of Aging</i> , 2020, 93, e1-e9.	3.1	11

#	ARTICLE	IF	CITATIONS
91	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic Repeat Expansion Adult Carriers. <i>Annals of Neurology</i> , 2020, 88, 113-122.	5.3	19
92	Microglial Hyperreactivity Evolved to Immunosuppression in the Hippocampus of a Mouse Model of Accelerated Aging and Alzheimer's Disease Traits. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 622360.	3.4	9
93	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2020, 133, 384-398.	2.4	26
94	Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases. <i>Molecular Neurobiology</i> , 2019, 56, 2811-2821.	4.0	20
95	Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer's disease patients: A comparison between visual and quantitative assessment. <i>NeuroImage: Clinical</i> , 2019, 23, 101927.	2.7	29
96	Novel P397S MAPT variant associated with late onset and slow progressive frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1559-1565.	3.7	6
97	A unique common ancestor introduced P301L mutation in MAPT gene in frontotemporal dementia patients from Barcelona (Baix Llobregat, Spain). <i>Neurobiology of Aging</i> , 2019, 84, 236.e9-236.e15.	3.1	7
98	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. <i>Lancet Neurology</i> , The, 2019, 18, 1103-1111.	10.2	128
99	Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid- β^2 positivity. <i>Cortex</i> , 2019, 121, 117-124.	2.4	12
100	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. <i>NeuroImage</i> , 2019, 189, 645-654.	4.2	33
101	Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 211-225.	2.6	10
102	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 997-1004.	1.9	19
103	Education modulates brain maintenance in presymptomatic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1124-1130.	1.9	23
104	Regional patterns of 18F-florbetaben uptake in presenilin 1 mutation carriers. <i>Neurobiology of Aging</i> , 2019, 81, 1-8.	3.1	5
105	Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 698-707.	3.7	42
106	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. <i>Brain</i> , 2019, 142, 1121-1133.	7.6	45
107	Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101777.	2.7	29
108	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 180-190.	2.4	84

#	ARTICLE	IF	CITATIONS
109	CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. <i>NeuroImage: Clinical</i> , 2019, 23, 101801.	2.7	26
110	Clinical and video-polysomnographic analysis of rapid eye movement sleep behavior disorder and other sleep disturbances in dementia with Lewy bodies. <i>Sleep</i> , 2019, 42, .	1.1	30
111	Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment. <i>European Journal of Neurology</i> , 2019, 26, 1098-1104.	3.3	20
112	ICâ€²â€²05: GENDER DIFFERENCES IN THE ASSOCIATION BETWEEN LONGITUDINAL BRAIN CHANGES AND BASELINE LEVELS OF CSF ALZHEIMER'S DISEASE AND GLIAL BIOMARKERS IN HEALTHY ELDERLS. <i>Alzheimer's and Dementia</i> , 2019, 15, P4.	0.8	0
113	Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 94.	6.2	20
114	APPâ€²derived peptides reflect neurodegeneration in frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2518-2530.	3.7	13
115	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. <i>NeuroImage: Clinical</i> , 2019, 24, 102077.	2.7	27
116	Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients. <i>Biomolecules</i> , 2019, 9, 800.	4.0	8
117	CSF-ApoER2 fragments as a read-out of reelin signaling: Distinct patterns in sporadic and autosomal-dominant Alzheimer disease. <i>Clinica Chimica Acta</i> , 2019, 490, 6-11.	1.1	3
118	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 546-560.	3.8	115
119	Does ALSâ€²FUS without <i>FUS</i> mutation represent ALSâ€²FET? Report of three cases. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 421-426.	3.2	5
120	Challenges associated with biomarkerâ€²based classification systems for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 346-357.	2.4	37
121	Poly(GP), neurofilament and grey matter deficits in <i>C9orf72</i> expansion carriers. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 583-597.	3.7	48
122	Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. <i>Alzheimer's and Dementia</i> , 2018, 14, 751-763.	0.8	61
123	Structural Connectivity Alterations Along the Alzheimerâ€²s Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid-Î² and Tau. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1575-1587.	2.6	25
124	Tauopathy with Hippocampal 4â€²Repeat Tau Immunoreactive Spherical Inclusions in a Patient with PSP. <i>Brain Pathology</i> , 2018, 28, 284-286.	4.1	4
125	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	10.2	97
126	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. <i>Neurobiology of Aging</i> , 2018, 66, 181.e3-181.e10.	3.1	19

#	ARTICLE	IF	CITATIONS
127	Validation of Î±-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease. <i>Molecular Neurobiology</i> , 2018, 55, 2249-2257.	4.0	34
128	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. <i>Neurobiology of Aging</i> , 2018, 62, 245.e1-245.e7.	3.1	16
129	P2â€³47: THE HIPPOCAMPAL LONGITUDINAL AXIS: RELEVANCE FOR UNDERLYING TAU AND TDPâ€³43 PATHOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P819.	0.8	0
130	P1â€³146: WHOLE EXOME SEQUENCING IN PATIENTS WITH EARLYâ€³ONSET ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA: MUTATION DETECTION IN CAUSAL AND RISK GENES FOR DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P332.	0.8	0
131	P2â€³262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM. <i>Alzheimer's and Dementia</i> , 2018, 14, P777.	0.8	0
132	P3â€³394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1248.	0.8	0
133	P1â€³432: REGIONAL PATTERNS OF 18Fâ€³FLORBETABEN UPTAKE IN PRESENILIN 1â€³MUTATION CARRIERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P475.	0.8	0
134	O3â€³09â€³03: SERUM NEUROFILAMENT LIGHT LEVELS CORRELATE WITH SEVERITY MEASURES AND NEURODEGENERATION MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1037.	0.8	0
135	Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimerâ€³s disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 113.	6.2	54
136	Prevalence of amyloidâ€³2 pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740.	5.3	132
137	Variably proteaseâ€³sensitive prionopathy presenting within ALS/FTD spectrum. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1297-1302.	3.7	10
138	P2â€³230: CHALLENGES ASSOCIATED WITH BIOMARKERâ€³BASED CLASSIFICATIONS SYSTEMS FOR ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P756.	0.8	0
139	Alpha-synuclein Aggregates in Labial Salivary Glands of Idiopathic Rapid Eye Movement Sleep Behavior Disorder. <i>Sleep</i> , 2018, 41, .	1.1	18
140	Interrupted CAG expansions in ATXN2 gene expand the genetic spectrum of frontotemporal dementias. <i>Acta Neuropathologica Communications</i> , 2018, 6, 41.	5.2	21
141	The hippocampal longitudinal axisâ€³relevance for underlying tau and TDP-43 pathology. <i>Neurobiology of Aging</i> , 2018, 70, 1-9.	3.1	21
142	Systematic Screening of Ubiquitin/p62 Aggregates in Cerebellar Cortex Expands the Neuropathological Phenotype of the C9orf72 Expansion Mutation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 703-709.	1.7	18
143	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. <i>Neurobiology of Aging</i> , 2018, 69, 293.e9-293.e11.	3.1	15
144	AdaptaciÃ³n y validaciÃ³n de la Frontotemporal Dementia Rating Scale (FTD-FRS) al castellano. <i>NeurologÃ­a</i> , 2017, 32, 290-299.	0.7	5

#	ARTICLE	IF	CITATIONS
145	Active A β immunotherapy CAD106 in Alzheimer's disease: A phase 2b study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 10-22.	3.7	102
146	The <i>APOE</i> ϵ 4 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 50-59.	2.4	36
147	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1065-1074.	2.6	5
148	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 543-555.	2.6	10
149	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 1251-1260.	0.8	47
150	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. <i>Acta Neuropathologica</i> , 2017, 134, 475-487.	7.7	53
151	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. <i>Scientific Reports</i> , 2017, 7, 2477.	3.3	28
152	CSF sAPP β , YKL-40, and neurofilament light in frontotemporal lobar degeneration. <i>Neurology</i> , 2017, 89, 178-188.	1.1	100
153	<i>TBK1</i> Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , 2017, 38, 297-309.	2.5	87
154	Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. <i>Annals of Neurology</i> , 2017, 82, 419-428.	5.3	161
155	Frontotemporal Dementia Caused by the P301L Mutation in <i>MAPT</i> Gene: Clinicopathological Features of 13 Cases from the Same Geographical Origin in Barcelona, Spain. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 213-221.	1.5	31
156	Adaptation and validation of a Spanish-language version of the Frontotemporal Dementia Rating Scale (FTD-FRS). <i>Neurología (English Edition)</i> , 2017, 32, 290-299.	0.4	3
157	[P417]: A PRESCREENING STUDY IN SPAIN TO IDENTIFY INDIVIDUALS WHO MIGHT BE SUITABLE FOR PARTICIPATION IN CLINICAL STUDIES IN EARLY ALZHEIMER'S DISEASE UTILIZING REFERRALS FROM GENERAL PRACTITIONER NETWORKS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1345.	0.8	0
158	[P418]: SYMPTOM ONSET IN GENETIC FRONTOTEMPORAL DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1337.	0.8	2
159	Neuronal intranuclear (hyaline) inclusion disease and fragile X-associated tremor/ataxia syndrome: a morphological and molecular dilemma. <i>Brain</i> , 2017, 140, e51-e51.	7.6	43
160	CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. <i>Molecular Neurobiology</i> , 2017, 54, 6647-6654.	4.0	45
161	Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations. <i>Molecular Neurobiology</i> , 2017, 54, 5550-5562.	4.0	119
162	[P419]: VISUAL AND QUANTITATIVE ASSESSMENT OF HIPPOCAMPAL ATROPHY IN EARLY ONSET ALZHEIMER'S DISEASE PATIENTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P789.	0.8	0

#	ARTICLE	IF	CITATIONS
163	[P4â€“214]: TOWARD A FUNCTIONAL NEUROMARKER FOR PRECLINICAL AD: EIGENVECTOR CENTRALITY REVEALS PRECLINICAL DIFFERENCES OF FUNCTIONAL INFORMATION FLOW IN THE HIPPOCAMPUS, PRECUNEUS, CEREBELLUM AND INFERIOR PARIETAL LOBULE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1348.	0.8	0
164	[P1â€“413]: VISUAL PATTERNS OF FLORBETABEN UPTAKE IN PRESENILIN 1 MUTATION CARRIERS. <i>Alzheimer's and Dementia</i> , 2017, 13, P435.	0.8	0
165	YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. <i>Molecular Neurodegeneration</i> , 2017, 12, 83.	10.8	140
166	Clinical Neuropathology image 4-2017: High-resolution 7 Tesla MRI of postmortem brain specimens: improving neuroimaging-neuropathology correlations. , 2017, 36, 162-163.		1
167	Sporadic MM2â€“thalamicâ€“+â€“cortical Creutzfeldtâ€“Jakob disease: Utility of diffusion tensor imaging in the detection of cortical involvement <i>in vivo</i>. <i>Neuropathology</i> , 2016, 36, 199-204.	1.2	11
168	<scp>sTREM</scp> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in earlyâ€“stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , 2016, 8, 466-476.	6.9	392
169	Quantitative Magnetic Resonance Abnormalities in Creutzfeldt-Jakob Disease and Fatal Insomnia. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 431-443.	2.6	17
170	White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 827-835.	2.6	17
171	IC-02-05: Cerebrospinal Fluid Strem2 Levels are Associated with Gray Matter Volume Increases and Reduced Diffusivity in Early Alzheimerâ€™s Disease. , 2016, 12, P8-P8.		0
172	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimerâ€™s disease. <i>Acta Neuropathologica</i> , 2016, 132, 213-224.	7.7	83
173	Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimerâ€™s disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 66.	10.8	9
174	Gerstmannâ€“Strâ€“usslerâ€“Scheinker Disease Presenting with Atypical Parkinsonism, but Typical Magnetic Resonance Imaging Findings of Prion Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 93-95.	1.5	4
175	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 623-636.	3.7	207
176	Preservation of cell-survival mechanisms by the presenilin-1 K239N mutation may cause its milder clinical phenotype. <i>Neurobiology of Aging</i> , 2016, 46, 169-179.	3.1	5
177	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 1259-1272.	0.8	86
178	Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. <i>Neurodegenerative Diseases</i> , 2016, 16, 69-76.	1.4	36
179	Assessing the role of TUBA4A gene in frontotemporal degeneration. <i>Neurobiology of Aging</i> , 2016, 38, 215.e13-215.e14.	3.1	9
180	CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. <i>Neurobiology of Aging</i> , 2016, 38, 47-55.	3.1	54

#	ARTICLE	IF	CITATIONS
181	Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2016, 53, 5902-5911.	4.0	15
182	Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic. <i>Molecular Neurobiology</i> , 2016, 53, 2189-2199.	4.0	80
183	O3-13-06: Targeted re-sequencing of sorl1 in early-onset Alzheimer's dementia: The european early onset dementia consortium. , 2015, 11, P253-P253.		0
184	Rare Variants in <i>PLD3</i> Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. <i>Human Mutation</i> , 2015, 36, 1226-1235.	2.5	23
185	Clinicopathological Correlations and Concomitant Pathologies in Rapidly Progressive Dementia: A Brain Bank Series. <i>Neurodegenerative Diseases</i> , 2015, 15, 350-360.	1.4	35
186	Diagnostic accuracy of behavioral variant frontotemporal dementia consortium criteria (FTDC) in a clinicopathological cohort. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 882-892.	3.2	26
187	Evolving brain structural changes in PSEN1 mutation carriers. <i>Neurobiology of Aging</i> , 2015, 36, 1261-1270.	3.1	30
188	Analysis of the <i>CHCHD10</i> gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. <i>Brain</i> , 2015, 138, e400-e400.	7.6	56
189	Genetic variability in <i>SQSTM1</i> and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. <i>Neurobiology of Aging</i> , 2015, 36, 2005.e15-2005.e22.	3.1	34
190	Rapidly progressive dementia with psychotic onset in a patient with the C9ORF72 mutation. , 2015, 34, 294-297.		7
191	Usefulness of Biomarkers in the Diagnosis and Prognosis of Early-Onset Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 919-927.	2.6	32
192	Determination of Neuronal Antibodies in Suspected and Definite Creutzfeldt-Jakob Disease. <i>JAMA Neurology</i> , 2014, 71, 74.	9.0	59
193	In vivo decreased dopamine transporter uptake in corticobasal degeneration presenting with primary progressive aphasia without parkinsonism. <i>European Journal of Neurology</i> , 2014, 21, e56-e57.	3.3	1
194	Reply. <i>Annals of Neurology</i> , 2014, 75, 460-461.	5.3	0
195	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. <i>Science Translational Medicine</i> , 2014, 6, 243ra86.	12.4	600
196	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. <i>Neurobiology of Aging</i> , 2014, 35, 444.e1-444.e4.	3.1	92
197	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. <i>Acta Neuropathologica</i> , 2014, 127, 407-418.	7.7	123
198	Large APP locus duplication in a sporadic case of cerebral haemorrhage. <i>Neurogenetics</i> , 2014, 15, 145-149.	1.4	12

#	ARTICLE	IF	CITATIONS
199	Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. <i>Human Molecular Genetics</i> , 2014, 23, 749-754.	2.9	98
200	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 684-691.	1.9	55
201	Cerebrospinal Fluid Level of YKL-40 Protein in Preclinical and Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 901-908.	2.6	102
202	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. <i>Neurobiology of Aging</i> , 2014, 35, 2657.e13-2657.e19.	3.1	34
203	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2014, 128, 397-410.	7.7	93
204	O4-11-04: ACTIVE A β IMMUNOTHERAPY CAD106 PHASE II DOSE-ADJUVANT FINDING STUDY: SAFETY AND CNS BIOMARKERS. , 2014, 10, P274-P274.		2
205	TARDBP mutation p.L383V associated with semantic dementia and complex proteinopathy. <i>Neuropathology and Applied Neurobiology</i> , 2014, 40, 225-230.	3.2	48
206	Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. <i>PLoS ONE</i> , 2014, 9, e89741.	2.5	407
207	Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2013, 74, 655-668.	5.3	171
208	A Pan-European Study of the C9orf72 Repeat Associated with FTL: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. <i>Human Mutation</i> , 2013, 34, 363-373.	2.5	247
209	Atypical neuropathological sCJD-MM phenotype with abundant white matter Kuru-type plaques sparing the cerebellar cortex. <i>Neuropathology</i> , 2013, 33, 204-208.	1.2	8
210	Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , 2013, 125, 201-213.	7.7	103
211	A preliminary study of the whole-genome expression profile of sporadic and monogenic early-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 1772-1778.	3.1	87
212	Distinctive age-related temporal cortical thinning in asymptomatic granulin gene mutation carriers. <i>Neurobiology of Aging</i> , 2013, 34, 1462-1468.	3.1	18
213	Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 443-453.	10.2	602
214	Neuroimaging and Biochemical Markers in the Three Variants of Primary Progressive Aphasia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 35, 106-117.	1.5	53
215	Cognitive Reserve Proxies Relate to Gray Matter Loss in Cognitively Healthy Elderly with Abnormal Cerebrospinal Fluid Amyloid- β Levels. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 715-726.	2.6	40
216	Donepezil Treatment Stabilizes Functional Connectivity During Resting State and Brain Activity During Memory Encoding in Alzheimer's Disease. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 199-205.	1.4	40

#	ARTICLE	IF	CITATIONS
217	Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia. <i>European Journal of Neurology</i> , 2013, 20, 1459.	3.3	11
218	Rare Variants in Calcium Homeostasis Modulator 1 (CALHM1) Found in Early Onset Alzheimer's Disease Patients Alter Calcium Homeostasis. <i>PLoS ONE</i> , 2013, 8, e74203.	2.5	26
219	Evolving Brain Functional Abnormalities in PSEN1 Mutation Carriers: A Resting and Visual Encoding fMRI Study. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 165-175.	2.6	19
220	Rapidly Progressive Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2012, 26, 267-271.	1.3	40
221	Inherited prion disease with 4-octapeptide repeat insertion linked to valine at codon 129. <i>Brain</i> , 2012, 135, e212-e212.	7.6	8
222	Breakpoint Sequence Analysis of an A β PP Locus Duplication Associated with Autosomal Dominant Alzheimer's Disease and Severe Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 303-308.	2.6	10
223	Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. <i>Brain</i> , 2012, 135, 3051-3061.	7.6	135
224	Identifying Earlier Alzheimer's Disease: Insights from the Preclinical and Prodromal Phases. <i>Neurodegenerative Diseases</i> , 2012, 10, 158-160.	1.4	12
225	PSEN1 Mutation Carriers Present Lower Cerebrospinal Fluid Amyloid- β 42 Levels than Sporadic Early-Onset Alzheimer's Disease Patients but no Differences in Neuronal Injury Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 605-616.	2.6	6
226	The amyloid- β isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease. <i>Molecular Medicine Reports</i> , 2012, 5, 1111-1115.	2.4	17
227	Serum Progranulin Levels in Patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease: Detection of GRN Mutations in a Spanish Cohort. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 581-591.	2.6	31
228	Distinct Functional Activity of the Precuneus and Posterior Cingulate Cortex During Encoding in the Preclinical Stage of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 517-526.	2.6	59
229	Hirano body-rich subtypes of Creutzfeldt-Jakob disease. <i>Neuropathology and Applied Neurobiology</i> , 2012, 38, 153-161.	3.2	8
230	Preclinical MSA in definite Creutzfeldt-Jakob disease. <i>Neuropathology</i> , 2012, 32, 158-163.	1.2	17
231	Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 127-134.	2.7	38
232	PICOGEN: Five years experience with a genetic counselling program for dementia. <i>Neurologia (English)</i> Tj ETQq0 0,0 rGbt /Oyrlck 10	0.4	10
233	Cognitively Preserved Subjects with Transitional Cerebrospinal Fluid A β -Amyloid 1-42 Values Have Thicker Cortex in Alzheimer's Disease Vulnerable Areas. <i>Biological Psychiatry</i> , 2011, 70, 183-190.	1.3	93
234	A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease. <i>Neuroscience Letters</i> , 2011, 496, 40-42.	2.1	13

#	ARTICLE	IF	CITATIONS
235	Focusing on atypical symptoms for improved diagnosis of early-onset Alzheimer's disease. <i>Future Neurology</i> , 2011, 6, 575-578.	0.5	4
236	Cerebrospinal Fluid Biomarkers and Memory Present Distinct Associations along the Continuum from Healthy Subjects to AD Patients. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 319-326.	2.6	66
237	PICOGEN: experiencia de 5 años de un programa de asesoramiento genético en demencia. <i>Neurología</i> , 2011, 26, 143-149.	0.7	28
238	Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. <i>Psychiatry Research - Neuroimaging</i> , 2011, 192, 140-146.	1.8	19
239	Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. <i>Journal of Neural Transmission</i> , 2011, 118, 259-262.	2.8	49
240	Neuropsychological profile of prodromal Alzheimer's disease (Prd-AD) and their radiological correlates. <i>Archives of Gerontology and Geriatrics</i> , 2011, 52, 190-196.	3.0	30
241	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease Families with <i>PSEN1</i> Mutations. <i>Neurodegenerative Diseases</i> , 2011, 8, 202-207.	1.4	24
242	Clinical features and <i>APOE</i> genotype of pathologically proven early-onset Alzheimer disease. <i>Neurology</i> , 2011, 76, 1720-1725.	1.1	123
243	Clinical, Neuropathologic, and Biochemical Profile of the Amyloid Precursor Protein I716F Mutation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 53-59.	1.7	52
244	Increased Cortical Thickness and Caudate Volume Precede Atrophy in <i>PSEN1</i> Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 909-922.	2.6	136
245	The memory alteration test (M@T) discriminates between subjective memory complaints, mild cognitive impairment and Alzheimer's disease. <i>Archives of Gerontology and Geriatrics</i> , 2010, 50, 171-174.	3.0	38
246	A novel <i>PSEN1</i> mutation (K239N) associated with Alzheimer's disease with wide range age of onset and slow progression. <i>European Journal of Neurology</i> , 2010, 17, 994-996.	3.3	21
247	New mutation in the <i>PSEN1</i> (E120G) gene associated with early onset Alzheimer's disease. <i>Neurología (English Edition)</i> , 2010, 25, 13-16.	0.4	4
248	Cognitive reserve modulates task-induced activations and deactivations in healthy elders, amnesic mild cognitive impairment and mild Alzheimer's disease. <i>Cortex</i> , 2010, 46, 451-461.	2.4	136
249	Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. <i>Neurobiology of Aging</i> , 2010, 31, 725-731.	3.1	196
250	Voxel based morphometry features and follow-up of amnesic patients at high risk for Alzheimer's disease conversion. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 875-884.	2.7	23
251	Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. <i>Journal of Neurology</i> , 2009, 256, 1620-1628.	3.6	77
252	Interactions of cognitive reserve with regional brain anatomy and brain function during a working memory task in healthy elders. <i>Biological Psychology</i> , 2009, 80, 256-259.	2.2	81

#	ARTICLE	IF	CITATIONS
253	Molecular evidence of founder effects of fatal familial insomnia through SNP haplotypes around the D178N mutation. <i>Neurogenetics</i> , 2008, 9, 109-118.	1.4	16
254	Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration. <i>Journal of Neurology</i> , 2008, 255, 488-494.	3.6	40
255	Naming Is Associated with Left Temporal Pole Metabolite Levels in Neurodegenerative Diseases. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 212-217.	1.5	12
256	First demonstrated de novo insertion in the prion protein gene in a young patient with dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 845-846.	1.9	11
257	Cortical Brain Metabolism as Measured by Proton Spectroscopy Is Related to Memory Performance in Patients with Amnesic Mild Cognitive Impairment and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 274-279.	1.5	41
258	Longitudinal Study of Amnesic Patients at High Risk for Alzheimer's Disease: Clinical, Neuropsychological and Magnetic Resonance Spectroscopy Features. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 402-410.	1.5	42
259	MAPT gene duplications are not a cause of frontotemporal lobar degeneration. <i>Neuroscience Letters</i> , 2007, 424, 61-65.	2.1	14
260	Screening for amnesic mild cognitive impairment and early Alzheimer's disease with M@T (Memory) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 294-304.	2.7	124
261	CSF analysis in patients with sporadic CJD and other transmissible spongiform encephalopathies. <i>European Journal of Neurology</i> , 2007, 14, 121-124.	3.3	61
262	A novel <i>MAPT</i> mutation (P301T) associated with familial frontotemporal dementia. <i>European Journal of Neurology</i> , 2007, 14, e9-10.	3.3	16
263	A novel mutation in the <i>PSEN1</i> gene (L286P) associated with familial early-onset dementia of Alzheimer type and lobar haematomas. <i>European Journal of Neurology</i> , 2007, 14, 1409-1412.	3.3	23
264	Late-onset frontotemporal dementia associated with a novel PGRN mutation. <i>Journal of Neural Transmission</i> , 2007, 114, 1051-1054.	2.8	13
265	Brain tau expression and correlation with the H1/H1 tau genotype in frontotemporal lobar degeneration patients. <i>Journal of Neural Transmission</i> , 2007, 114, 1585-1588.	2.8	6
266	Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. <i>Journal of Neurology</i> , 2007, 254, 901-906.	3.6	72
267	From Progressive Nonfluent Aphasia to Corticobasal Syndrome: A Case Report of Corticobasal Degeneration. <i>Neurocase</i> , 2006, 12, 355-359.	0.6	25
268	Ancestral origins of the prion protein gene D178N mutation in the Basque Country. <i>Human Genetics</i> , 2005, 117, 61-69.	3.8	7
269	Discrepancies in the Clinical Utility of the 14-3-3 Protein for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease. <i>Archives of Neurology</i> , 2004, 61, 604.	4.5	3
270	Clinical and genetic features of human prion diseases in Catalonia: 1993-2002. <i>European Journal of Neurology</i> , 2004, 11, 649-655.	3.3	29

#	ARTICLE	IF	CITATIONS
271	CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS. <i>Journal of Neurology</i> , 2004, 251, 1278-1279.	3.6	28
272	Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. <i>Neurology</i> , 2003, 60, 230-234.	1.1	297
273	Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 73, 79-81.	1.9	37
274	14-3-3 protein isoforms and atypical patterns of the 14-3-3 assay in the diagnosis of Creutzfeldt-Jakob disease. <i>Neuroscience Letters</i> , 2002, 320, 69-72.	2.1	30
275	Analysis of the exon 1 polymorphism in the Tau gene in transmissible spongiform encephalopathies. <i>Journal of Neurology</i> , 2002, 249, 938-939.	3.6	13
276	14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. <i>Neurology</i> , 2001, 57, 722-724.	1.1	68
277	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 0, , .	0.8	2